🇺🇸 Ilaprazole Enteric-Coated Tablets in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Thrombocytopenia — 2 reports (25%)
2. Alanine Aminotransferase Increased — 1 report (12.5%)
3. Aspartate Aminotransferase Increased — 1 report (12.5%)
4. Death — 1 report (12.5%)
5. Granulocytopenia — 1 report (12.5%)
6. Myelosuppression — 1 report (12.5%)
7. Suspected Drug-Induced Liver Injury — 1 report (12.5%)

Source database →

Frequently asked questions

Is Ilaprazole Enteric-Coated Tablets approved in United States?

Ilaprazole Enteric-Coated Tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ilaprazole Enteric-Coated Tablets in United States?

The Third Xiangya Hospital of Central South University is the originator. The local marketing authorisation holder may differ — check the official source linked above.